Unique ID issued by UMIN | UMIN000030607 |
---|---|
Receipt number | R000034784 |
Scientific Title | A clinical study to evaluate the anti-obesity effect of capsules containing noni fruit powder |
Date of disclosure of the study information | 2019/02/17 |
Last modified on | 2023/07/03 11:27:02 |
A clinical study to evaluate the anti-obesity effect of capsules containing noni fruit powder
A clinical study to evaluate the anti-obesity effect of capsules containing noni fruit powder
A clinical study to evaluate the anti-obesity effect of capsules containing noni fruit powder
A clinical study to evaluate the anti-obesity effect of capsules containing noni fruit powder
Japan |
None
Adult |
Others
NO
To evaluate the anti-obesity effect of intakeof capsules containing noni fruit powder for 4 weeks
Efficacy
Body weight, BMI
Waist circumference, Visceral fat area, Total fat percentage, Total fat area
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Food |
Intake of capsules containing noni fruit powder for 4 weeks
20 | years-old | <= |
55 | years-old | > |
Male and Female
1) Subject whose age of 20 years or more and less than 55 years at informed consent
2) Subject whose BMI is 25 kg/m2 or more and less than 30 kg/m2
3) Subject who weighs less than 88 kg
4) Subject having a briefing of the content of the present study, fully understanding and agreeing to its objective and being able to personally sign a written informed consent
1) Subject who has a mental disease such as depression, schizophrenia, epilepsy or bulimia nervosa
2) Subject who has allergic disease, cardiovascular, respiratory, thyroid gland malfunction, diabetes, heart disease, brain disease, gout or sleep disorder
3) Subject who takes regularly medicinal drugs or pharmaceuticals having an effect on the weight
4) Subject who has the possibility of developing allergic symptoms by the test food (noni allergy)
5) Subject who has a snacking habit
6) Female subject who is pregnant or may be pregnant
7) Female subject who is in lactating
8) Subject who has blood sample of 200 ml or more within 1 month, or 400 ml or more within 3 months prior to the start of the present study (e.g. donated blood)
9) Subject who participated in other clinical trials within the past 4 months or currently participates in other clinical trials or plans to participate in other clinical trials during the examination period
10) Subject deemed unsuitable by the investigator
6
1st name | |
Middle name | |
Last name | Masahiro Fukuda |
Fukuda Clinic
Director
Shin-Osaka Brick Building 2F, 1-6-1, Miyahara, Yodogawa-ku, Osaka
06-6398-0203
fukuda@drmog.jp
1st name | |
Middle name | |
Last name | Tomohiro Sugino |
Soiken Inc.
R&D Division
Senri Life Science Center 13F, 1-4-2, Shinsenri-higashimachi, Toyonaka, Osaka
06-6871-8888
sugino@soiken.com
Soiken Inc.
ASKA Pharmaceutical Co., Ltd.
Profit organization
NO
2019 | Year | 02 | Month | 17 | Day |
Unpublished
Completed
2017 | Year | 09 | Month | 16 | Day |
2017 | Year | 09 | Month | 16 | Day |
2018 | Year | 01 | Month | 06 | Day |
2018 | Year | 02 | Month | 17 | Day |
2017 | Year | 12 | Month | 28 | Day |
2023 | Year | 07 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034784
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |